About JITC

Reviewer_2.png
The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Become a Reviewer

For_Authors.png
Help enrich communication and advance scientific understanding in cancer immunotherapy.

For Authors

Editor.png
JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

From the Editors

Collections.png
Readers have the opportunity to view JITC's special editions and theme-focused collections.

JITC Collections




Get to Know and Meet JITC Editors

Get to know JITC's phenomenal group of editors, lead by Editor-in-Chief, Michael T. Lotze, MD, and Deputy Editor-in-Chief, Sjoerd H. van der Burg, PhD. 

Interested in meeting our editors? From Geneva, Switzerland to National Harbor, Maryland, our editors will be available to meet with you and learn about your research. Check back for more information on Meet-the-Editor opportunities in 2025. 

Upcoming opportunities to meet JITC editors:

 
AACR 2025
Marcela V. Maus, MD, PhD – Section Editor for JITC's Immune Cell Therapies and Immune Cell Engineering Section
JITC Meet the Editor Activity
Monday, April 28: 12:30-1:30 pm 
SITC Exhibit Booth #2813
Chicago, IL   
 
AAI 2025
Michael T. Lotze, MD - JITC Editor-in-Chief / Daniel J. Powell, Jr., PhD – Associate Editor for JITC's Immune Cell Therapies and Immune Cell Engineering Section
SITC Symposium on Cellular Therapy for Solid Cancers: From Concepts to Approvals (Chairs)
Sunday, May 4: 7-8:30am 
Honolulu, HI 

ASCO 2025
Michael T. Lotze, MD - JITC Editor-in-Chief 
JITC Meet the Editor Activity
Saturday, May 31: 12-1pm CT
SITC Exhibit Booth #13026
Chicago, IL




JITC Awards

Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.

Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.

The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.



APC Discounts

As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 25 percent discount on Article Processing Charges (APCs) for all accepted JITC articles submitted in 2025. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author. 

JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. 

For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.



Highly Accessed Articles

What is the article Altmetric Attention Score?


Altmetric_Score_donut.pngIndicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

Article has an altmetric score of 139
Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins, Maciej Kmieciak, Monique Williams, Giovanni Archer, Lindsey Gwaltney, Patrick Dillon, Daniel Flora, Daniel Stover, Andrew S Poklepovic, Mary Hackney, Masey Ross, Hetal Vachhani, Raphael Louie, Kandace P McGuire, Amelia Grover, Tasnim Rahman and Amber Hendrix


 

Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer

Article has an altmetric score of 139
Vladimir Roudko, Diane Marie Del Valle, Emir Radkevich, Geoffrey Kelly, Xie Hui, Manishkumar Patel, Edgar Gonzalez-Kozlova, Kevin Tuballes, Howard Streicher, Swati Atale, Lisa Wang, Benito CzinCzin, Seunghee Kim-Schulze, Ignacio I Wistuba, Cara L Haymaker, Gheath Al-Atrash, Ganiraju Manyam, Jianjun Zhang, Ryan Thompson, Mayte Suarez-Farinas, Stephanie Lheureux and Sacha Gnjatic


 

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis

Article has an altmetric score of 15Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah, Jeff Clarke, Jeffrey Crawford, Thomas Stinchcombe, Betty C Tong, Xiaofei Wang, Lin Gu, Dennis Wigle, Konstantin H Dragnev, Scott J Antonia, Kent Weinhold and Neal Ready


 

Browse the Current Issue

No Data Found